HRGN Stock Overview
A clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Harvard Apparatus Regenerative Technology Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.80 |
| 52 Week High | US$5.90 |
| 52 Week Low | US$1.74 |
| Beta | -0.63 |
| 1 Month Change | -6.25% |
| 3 Month Change | -33.70% |
| 1 Year Change | -26.83% |
| 3 Year Change | -70.00% |
| 5 Year Change | -42.49% |
| Change since IPO | -98.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| HRGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.8% | 2.7% | 2.9% |
| 1Y | -26.8% | -6.7% | 10.0% |
Return vs Industry: HRGN underperformed the US Biotechs industry which returned -4.5% over the past year.
Return vs Market: HRGN underperformed the US Market which returned 9.6% over the past year.
Price Volatility
| HRGN volatility | |
|---|---|
| HRGN Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: HRGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HRGN's weekly volatility has decreased from 16% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 8 | Jerry He | hregen.com |
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company’s pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair. Its lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease.
Harvard Apparatus Regenerative Technology Inc. Fundamentals Summary
| HRGN fundamental statistics | |
|---|---|
| Market cap | US$28.65m |
| Earnings (TTM) | -US$7.73m |
| Revenue (TTM) | US$430.00k |
66.6x
P/S Ratio-3.7x
P/E RatioIs HRGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HRGN income statement (TTM) | |
|---|---|
| Revenue | US$430.00k |
| Cost of Revenue | US$270.00k |
| Gross Profit | US$160.00k |
| Other Expenses | US$7.89m |
| Earnings | -US$7.73m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 37.21% |
| Net Profit Margin | -1,798.14% |
| Debt/Equity Ratio | 0% |
How did HRGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/02 00:43 |
| End of Day Share Price | 2025/04/29 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Harvard Apparatus Regenerative Technology Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | Maxim Group |
| Pamela Bassett | Maxim Group |